Here
is a short list of funding opportunities that have deadlines in May. Every month during the active season (September- May) known funding opportunities are rounded up and
posted here on our online news.
Please note: This is not a comprehensive list. For more information about specific opportunities, check out our funding calendar.
If you have an opportunity you'd like to add, please contact:
Amy Wilson, Publications Coordinator, NSHA Research Services
May 2018
14-May: Canadian Cancer Society- Quality of Life Grants- Letter of Intent Deadline (Stage 1 of 2)
18-May: Dalhousie University Faculty of Medicine- Bridge Funding Deadline
1- June: Beatrice Hunter Cancer Research Institute Seed Funding Rolling Competition- $10,000- Cancer Research
No Deadline: Canadian Arrhythmia Network of Canada- Ignite Grant- $25,000- The
Ignite Grant aims to foster collaborative relationships between
Canadian-based companies and network investigators. An Ignite project
must focus on creating an innovative solution for a company-specific
problem through the generation of new knowledge or the application of
existing knowledge.
Showing posts with label dalhousie. Show all posts
Showing posts with label dalhousie. Show all posts
Monday, May 7, 2018
Monday, February 26, 2018
Local Researchers Changing the Game Post Hip & Knee Replacement
 | |
| Dr. David Anderson (Photo: Bruce Bottomley, courtesy Dalhousie) |
"This large, randomized, double-blind trial is likely to be practice-changing, because the point estimates for the relative safety and efficacy of the two treatments are precise and the included patients represent a typical population undergoing joint-replacement surgery." says Dr. David Garcia who commented on the results in an NEJM Editorial.
Lead author Dr. David Anderson (Dalhousie University Dean of Medicine), Dr. Michael Dunbar (NSHA Orthopedic Surgeon, Researcher and QEII Foundation Endowed Chair in Arthroplasty Outcomes) and their research teams at NSHA completed an interdisciplinary study between orthopaedics and hematology. The study was a joint effort conducted at 14 other institutions across several provinces (NS, ON, QC, NB, MB) and many participating sites commended NSHA Hematology Research Manager Susan Pleasance and her team on their excellent study management. NSHA's Research Methods Unit (RMU) contributed with sample size calculation, analytic design and
analysis of all results. They also contributed to data management activities of the
study, including database consulting and design, data reporting, data cleaning
and preparation for analysis.
This was an exceptional example of a large, interdisciplinary, inter provincial and multi-site cooperative research study.
The EPCAT II trial recruited patients from January 2013 through April 2016 and followed 3424 patients post knee and hip replacement in a multicentre, double blind, randomized control trial funded by CIHR.All enrolled patients had an initial 5 day course of Rivaroxaban, then randomized to continue on Rivaroxaban or switch to Aspirin for additional 9 days (knee-1620 patients) or 30 days (hip-1804 patients) and followed for 90 days post surgery.
The primary effectiveness outcome was the rate of symptomatic venous thromboembolism. Results show that the rates were similar between the two drugs. The primary safety outcome was a major or clinically important bleeding event both of which were also similar between the two drugs.
The EPCAT II trial builds on the EPCAT I trial which suggested that extended prophylaxis with Aspirin after total hip replacement was as safe and effective as heparin to prevent venous thromboembolism after an initial 10-day postoperative course of heparin.
"Going forward, the very low rates of bleeding and thrombosis seen with the relatively inexpensive and user-friendly aspirin-based strategy probably mean that the EPCAT II trial has established a prophylaxis regimen against which all strategies to prevent venous thromboembolism after joint replacement will be compared." (Dr. David Garcia)
Additional Media:
Tuesday, October 3, 2017
Researcher Profile- Dr. James Robar
What is your current research project?
I am involved in several research projects with the common theme of improving radiation therapy or radiosurgery. One recent effort is the development of a new technology to detect a patient’s body position during the delivery of high-energy x-ray beams, in order to monitor and ensure accuracy of treatment. Right now, my research team is focusing on stereotactic radiosurgery—a non-invasive treatment of benign or malignant tumours, as well as of conditions such as arteriovenous malformations (AVMs) or trigeminal neuralgia. The technology that we are developing allows us to read out the patient’s head position in three dimensions, 200 times per second and with sub-millimetre precision. If the patient moves, we will know, and can interrupt treatment. The technology uses an array of novel capacitive sensors.
How did you become interested in your research topic?
A few years ago, I came across a black paint that was highly electrically conductive. You could apply a thin layer to virtually any material, and then use the painted region, for example, as a switch by touching it. But when I experimented further, I realized that it was detecting the approach of my hand long before it had made contact, and with high sensitivity. This is basic physics! I then 3D-printed a ring-shaped prototype that could, for example, be placed around a patient’s head. The detector element was very thin, so it wouldn’t disturb the incoming radiation beams. At the time, my five-year-old Keira helped me paint on the eight detectors. With some basic data acquisition and math (mostly by me, not Keira), pretty soon we were creating doodles on a monitor by waving our hands in the air. It was fun and proved the concept.
What has been unexpected about your findings so far?
Since the human body allows a high capacitance, but plastic does not, the detector can effectively “see through” an immobilization mask that the patient may be wearing for treatment. This wasn’t a property that we originally thought about, but it is exactly what we want. It also provides a key competitive advantage – other real-time approaches have to monitor the patient’s skin, which gives a poor surrogate for the position of a brain tumour.
What’s innovative about your research?
Nobody has built a system like this before, to our knowledge. With the help of Dalhousie ILI, we filed a patent. Now, through collaboration with our industry partner Brainlab AG and with support from ACOA, we are working on this technology to bring the tech to patients worldwide.
One word that best describes how you work: matinal
What technology can’t you live without? The GPS chart plotter on my sailboat. It keeps me on target.
How do you envision your research benefiting the “public at large”?
We foresee all of our research projects as improving outcomes for patients, increasing efficiency of care, or improving the patient experience. Also, by doing the R&D within a graduate program, we educate many medical physics trainees – who will be the next generation of clinical physicists and innovators.
 |
| Dr. James Robar |
I am involved in several research projects with the common theme of improving radiation therapy or radiosurgery. One recent effort is the development of a new technology to detect a patient’s body position during the delivery of high-energy x-ray beams, in order to monitor and ensure accuracy of treatment. Right now, my research team is focusing on stereotactic radiosurgery—a non-invasive treatment of benign or malignant tumours, as well as of conditions such as arteriovenous malformations (AVMs) or trigeminal neuralgia. The technology that we are developing allows us to read out the patient’s head position in three dimensions, 200 times per second and with sub-millimetre precision. If the patient moves, we will know, and can interrupt treatment. The technology uses an array of novel capacitive sensors.
How did you become interested in your research topic?
A few years ago, I came across a black paint that was highly electrically conductive. You could apply a thin layer to virtually any material, and then use the painted region, for example, as a switch by touching it. But when I experimented further, I realized that it was detecting the approach of my hand long before it had made contact, and with high sensitivity. This is basic physics! I then 3D-printed a ring-shaped prototype that could, for example, be placed around a patient’s head. The detector element was very thin, so it wouldn’t disturb the incoming radiation beams. At the time, my five-year-old Keira helped me paint on the eight detectors. With some basic data acquisition and math (mostly by me, not Keira), pretty soon we were creating doodles on a monitor by waving our hands in the air. It was fun and proved the concept.
What has been unexpected about your findings so far?
Since the human body allows a high capacitance, but plastic does not, the detector can effectively “see through” an immobilization mask that the patient may be wearing for treatment. This wasn’t a property that we originally thought about, but it is exactly what we want. It also provides a key competitive advantage – other real-time approaches have to monitor the patient’s skin, which gives a poor surrogate for the position of a brain tumour.
What’s innovative about your research?
Nobody has built a system like this before, to our knowledge. With the help of Dalhousie ILI, we filed a patent. Now, through collaboration with our industry partner Brainlab AG and with support from ACOA, we are working on this technology to bring the tech to patients worldwide.
One word that best describes how you work: matinal
What technology can’t you live without? The GPS chart plotter on my sailboat. It keeps me on target.
How do you envision your research benefiting the “public at large”?
We foresee all of our research projects as improving outcomes for patients, increasing efficiency of care, or improving the patient experience. Also, by doing the R&D within a graduate program, we educate many medical physics trainees – who will be the next generation of clinical physicists and innovators.
Tuesday, September 19, 2017
Standout in Atlantic Canada: Dr. Robin Urquhart Receives $950,000+ from CIHR Foundation Grant Competition
 |
| Dr. Robin Urquhart |
CIHR’s mandate is to “excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system.” Dr. Urquhart will be using her $950,000+ award for her research program involving: “Follow-up care of cancer survivors: optimizing survivor and health system outcomes”.
The Foundation Grant Competition saw 600 applications submitted across Canada, 14 of which were from Nova Scotia. Only 76 across Canada were funded and Dr. Urquhart’s was the only funded application in Atlantic Canada. Each application went through a 3 stage review process where only successful applicants advanced to the subsequent stage.
Dr. Urquhart is an Assistant Professor and Ramia Scientist in the Department of Surgery, with cross-appointments in the Department of Community Health and Epidemiology and Division of Medical Education. She is also a Senior Scientist with the Beatrice Hunter Cancer Research Institute and an Affiliate Scientist at NSHA.
NSHA Research Services has been proud to support and work with Robin-
Congratulations to Robin and her team!
Tuesday, September 5, 2017
Welcome Dr. Thomas Marrie
 |
| Dr. Thomas Marrie |
Dr. Thomas Marrie is an accomplished researcher, administrator and infectious disease specialist. Having studied pneumonia for more than 4 decades, Dr. Marrie came full circle as the 14th Dean of Dalhousie Medical School (2009-2014) – the very institution where he studied medicine.
As Dean, he ended his tenure with several significant accomplishments. The first class of the expansion of Dalhousie Medical School (Dalhousie Medicine New Brunswick) graduated in 2014 and an increased number of African-Nova Scotians now are enrolling in medical school.
A priority as Dean was to increase research capacity and in 2013 Canada’s First Endowed Occupational Medicine Research Chair was established with J.D. Irving.
Dr. Marrie is a Fellow of the Canadian Academy of Health Sciences and served as the President of the board from 2011-2013.
Please join us in welcoming Dr. Marrie to NSHA!
Subscribe to:
Posts (Atom)